Companies

Proximagen Neuroscience

Overview

Proximagen is researching and developing treatments for neurodegenerative diseases. It is working on four main groups of compounds. PRX1 is for Parkinson's disease, PRX2 is for the treatment of dyskinesia or involuntary movements, PRX4 is for neuroprotection of human nerve cells and PRX5 is designed to reduce cognitive decline.

Sector: Health

News blog

• Proximagen Neurosciences Posted: 24/03/2009
• Proximagen Neuroscience Posted: 14/10/2008
• Proximagen Neuroscience Posted: 25/07/2008
• Proximagen Neuroscience Posted: 29/08/2007

Browse by sector

All companies

• Aim advisers
• Aim Awards
• Aim investor relations
• Cleantech
• Construction
• Consumer
• Electricals
• Financial
• Food
• Health
• Industrial
• Leisure
• Media
• Mobile
• Property
• QUOTED MICRO
• Resources
• Retail
• Security
• Services
• Technology
• Telecoms
• Training
• Transport

• 2.4mNumber of messages posted on SocialGo networks
  
• $38mCost savings generated by ideas from WalMart staff over a two month period